Quick Answer
AXIM BIOTECHNOLOGIES, INC. reported Cash and Equivalents of $47.3 thousand for fiscal year 2022.
AXIM BIOTECHNOLOGIES, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $47.3K | -89.6% |
| 2021 | $453.0K | -74.9% |
| 2018 | $1.81M | -12.3% |
| 2017 | $2.06M | +188.5% |
| 2016 | $713.3K | +431.7% |
| 2015 | $134.2K | -79.7% |
| 2014 | $661.1K | +520473.2% |
| 2013 | $127.00 | -99.3% |
| 2012 | $19.1K | -17.3% |
| 2011 | $23.1K | — |
| 2010 | $0.00 | — |
| 2010 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $53.5K | -86.9% | +13.2% |
| December 31, 2022 | $47.3K | -89.6% | -27.4% |
| June 30, 2022 | $65.2K | -67.8% | -84.0% |
| March 31, 2022 | $408.0K | -9.2% | -9.9% |
| December 31, 2021 | $453.0K | -0.9% | +33.9% |
| September 30, 2021 | $338.4K | -70.8% | +67.4% |
| June 30, 2021 | $202.2K | -77.3% | -55.0% |
| March 31, 2021 | $449.2K | — | -1.7% |
- AXIM BIOTECHNOLOGIES, INC. showed a decrease of -89.6% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from AXIM BIOTECHNOLOGIES, INC.’s fiscal year 2022 report (Form 10-K), filed with the SEC on April 17, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: